Shadiqul Hoque, MD
Medical Oncology · North Little Rock, ARNPI 1487918702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $917, 3.3 times the $279 reported in 2023. That places this record below the midpoint for medical oncology clinicians in AR, where the typical reported total is $1,872.
Across 49 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$138
- Gilead$117
- E.r. Squibb & Sons, L.L.C.$95
- GSK$92
- Novartis$80
- Genentech USA, Inc.$70
- plus $783 from 25 others
What the payments were for
- Food & beverage$1,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 5 | $138 |
| Gilead(2 entities) | 2 | $117 |
| E.r. Squibb & Sons, L.L.C. | 1 | $95 |
| GSK | 1 | $92 |
| Novartis | 3 | $80 |
| Genentech USA, Inc. | 3 | $70 |
| Johnson & Johnson | 2 | $66 |
| Eisai Inc. | 2 | $55 |
| Merck | 2 | $47 |
| AbbVie | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Incyte Corporation | 2 | $45 |
| Galvanize Therapeutics, Inc | 1 | $40 |
| Sobi, Inc | 2 | $39 |
| Pfizer | 2 | $38 |
| Bayer | 2 | $36 |
| Novocure Inc. | 1 | $33 |
| Sanofi | 1 | $31 |
| Agios Pharmaceuticals, Inc. | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $14 |
How this compares
$1,375 in reported general payments places this provider in the 45th percentile of 20 medical oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in North Little Rock
- Sunny R K SinghNorth Little Rock$784
- Anusha JillellaNorth Little Rock$584
- Muthu KumaranLittle Rock$193K
- Sunilkumar KakadiaHot Springs$31K
- Cesar Gentille SanchezLittle Rock$29K
- Stephen ToothakerSearcy$19K
- Ryan KochSearcy$15K
- Zaki SammanFort Smith$9K
- Kristen SagerMena$8K
- Chen HuangHarrison$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.